only enough [3%),:<3%), facial edema (> <3%), peripheral edema (> <3%), localized blanching Central nervous system: Altered sense of smell (> <3%), ataxia (> <3%), depression (> <3%), dizziness (> <3%), drowsiness (> <3%), headache (> <3%), insomnia (> <3%), malaise (> <3%), nervousness (> <3%), paresthesia (> <3%) Dermatologic: Contact dermatitis (> <3%), dermatitis (> <3%) Gastrointestinal: Constipation (> <3%), dysgeusia (> <3%), nausea (> <3%) Neuromuscular & skeletal: Myalgia (> <3%), weakness (> <3%) Ophthalmic: Blurred vision, conjunctivitis, dry eye syndrome, eyelid edema, eye discharge, foreign body sensation of eye, lacrimation Respiratory: Asthma (> <3%), dry nose (> <3%), dyspnea (> <3%), pharyngitis (> <3%), rhinitis (> <3%)> <1% (Limited to important or life-threatening): Blepharitis, blepharoconjunctivitis, bradycardia, conjunctival edema, corneal erosion, corneal infiltrates, corneal staining, crusting of eyelid, epithelial keratopathy, erythema of eyelid, eyelid disease, eyelid retraction, eye irritation, eye pain, follicular conjunctivitis, hypersensitivity reaction, keratitis, ocular edema, photophobia, scaling of eyelid, visual disturbance Warnings/Precautions Concerns related to adverse effects: CNS effects: May cause dizziness and somnolence, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Hypersensitivity reactions: Use may lead to allergic-like reactions, including hyperemia, pruritus, discomfort, tearing, foreign body sensation, and edema of the lid and conjunctiva; if these symptoms occur, discontinue use. Disease-related concerns: Cardiovascular disease: Use with caution in patients with severe uncontrolled cardiovascular disease (eg, hypertension), coronary insufficiency, recent myocardial infarction, cerebrovascular disease, Raynaud disease, and thromboangiitis obliterans. Depression: Use with caution in depressed patients and monitor signs/symptoms of depression; therapy is associated infrequently with depression. Hepatic impairment: Close monitoring of cardiovascular parameters is recommended in patients with hepatic impairment; clonidine (structurally related to apraclonidine) administered systemically undergoes partial hepatic metabolism. Renal impairment: Close monitoring of cardiovascular parameters is recommended in patients with renal impairment; use with caution in patients with chronic renal failure. Topical apraclonidine has not been studied in patients with renal impairment; however, the half-life of clonidine (structurally related to apraclonidine) administered systemically is increased significantly in severe impairment. Vasovagal reactions: Potential for a vasovagal attack to occur; use with caution in patients with history of vasovagal reactions. Concurrent drug therapy issues: Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. Special populations: Contact lens wearers: Some products contain benzalkonium chloride which may be absorbed by soft contact lenses; contact lenses should be removed during instillation; may be reinserted 15 minutes after instillation. Other warnings/precautions: Appropriate use: For topical ophthalmic use only; not for injection or oral administration. Tachyphylaxis: The IOP-lowering efficacy may decrease over time in some patients; most patients experience a benefit for less than one month; routinely monitor IOP. Monitoring Parameters Closely monitor patients who develop exaggerated reductions in intraocular pressure; visual fields (periodically for glaucoma patients on maximally tolerated medical therapy using 0.5% solution to delay surgery); tachyphylaxis; cardiovascular parameters in patients with renal and/or hepatic impairment; depression in depressed patients. Pregnancy Considerations Adverse events have been observed in animal reproduction studies. If ophthalmic agents are needed during pregnancy, the minimum effective dose should be used in combination with punctual occlusion to decrease potential exposure to the fetus (Samples 1988). Patient Education Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?) Patient may experience blurred vision, dry eyes, increased tears, or dry mouth. Have patient report immediately to prescriber vision changes, eye pain, severe eye irritation, eyelid edema, eye discharge, or foreign body sensation in eye (HCAHPS). Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions. Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients. Next Interactions Print this page Add to My Med List More about apraclonidine ophthalmic Side Effects During Pregnancy or Breastfeeding Dosage Information Drug Interactions Support Group Pricing & Coupons En Español 0 Reviews Add your own review/rating Drug class: ophthalmic glaucoma agents Consumer resources Apraclonidine ophthalmic Apraclonidine Apraclonidine Ophthalmic (Advanced Reading) Professional resources Apraclonidine Hydrochloride (AHFS Monograph) Apraclonidine (FDA) Other brands: Iopidine Related treatment guides Glaucoma Postoperative Increased Intraocular Pressure> ] Drug Status Rx Availability Prescription only C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Apraclonidine ophthalmic Rating No Reviews - Be the first! 8.0 /10 No Reviews - Be the first! 8.0 Rate it! Manufacturers Akorn, Inc. Sandoz Inc. Drug Class Ophthalmic glaucoma agents Related Drugs ophthalmic glaucoma agents timolol ophthalmic , Lumigan , latanoprost ophthalmic , Travatan , brimonidine ophthalmic , Xalatan Glaucoma Combigan , nadolol , pilocarpine ophthalmic , acetazolamide , Diamox , mitomycin ophthalmic , Corgard , methazolamide , physostigmine ophthalmic , carbachol ophthalmic , Diamox Sequels , More... Postoperative Increased Intraocular Pressure Ilevro , Nevanac , nepafenac ophthalmic , Iopidine , More... because of
prison Apraclonidine and have become
EmoticonEmoticon